Royalty Pharma (RPRX) Total Non-Current Liabilities (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Total Non-Current Liabilities data on file, last reported at $9.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 18.31% year-over-year to $9.2 billion; the trailing twelve-month figure through Mar 2026 stood at $9.2 billion (up 18.31% YoY), and the FY2025 full-year result was $9.8 billion, up 24.17% from the prior year.
• Total Non-Current Liabilities eased to $9.2 billion in Q1 2026, from $9.8 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $9.8 billion in Q4 2025 to a low of $6.3 billion in Q3 2023.
• A 5-year average of $7.7 billion and a median of $7.5 billion in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slipped 13.62% in 2023 and climbed 25.15% in 2024, its largest moves.
• Tracing RPRX's Total Non-Current Liabilities over 5 years: stood at $7.3 billion in 2022, then retreated by 13.57% to $6.3 billion in 2023, then increased by 25.15% to $7.9 billion in 2024, then gained by 24.17% to $9.8 billion in 2025, then declined by 5.67% to $9.2 billion in 2026.
• Business Quant data shows RPRX's Total Non-Current Liabilities at $9.2 billion in Q1 2026, $9.8 billion in Q4 2025, and $9.2 billion in Q3 2025.